Munich Cancer Registry



- ▶ Survival
- ▶ Selection Matrix
- ▶ Homepage

Munich Cancer Registry at Munich Cancer Center Marchioninistr. 15 Munich, 81377 Germany

http://www.tumorregister-muenchen.de/en

Cancer statistics: Baseline statistics

C21: Anal cancer

Year of diagnosis	1998-2012
Patients	1,184
Diseases	1,184
Creation date	03/20/2014
Export date	02/12/2014
Population	4.5 m



http://www.tumorregister-muenchen.de/en/facts/base/base_C21__E.pdf

Global Statements about the statistics on the Internet – Baseline Statistics (grey button —), Survival (red button —)

In these analyses, the clinics and physicians of Upper Bavaria and the city and county of Landshut[#], with a total of 4.5 million inhabitants, account for the frequency of cancer diseases^{##} and the achieved long term results. Additionally, the long term survival evaluated by the Munich Cancer Registry (MCR) is compared with the results of the population-based registry in the USA (SEER), which is useful for checking the consistency of the data on an international level.

In comparing several tables, inconsistent figures may be detected. This is based on the fact that different patient cohorts are included in the base calculation, for example when proportions of multiple tumors or DCO-cases**** are concerned. In other cases the individual tumor diagnosis is the basis for calculation, for example with incidence.

The foot notes describe the currentness of the data. The baseline statistics and survival data are updated annually. This yearly analysis comprises the Annual Report of the MCR. The time-delayed acquisition of data and the occasionally high DCO-rates indicate optimizing reserves, among others, because of current financial and legal conditions that hinder the analyses.

Clinics and physicians have access to essentially more detailed data, with which they can check, compare and in the best case optimize their own data and results.

We would be pleased to receive corrections, critique and useful suggestions. Just send an e-mail to tumor@ibe.med.uni-muenchen.de.

Munich Cancer Registry, March 2014

- Base data has been collected since 1998. An increase in new diseases is apparent, which is an effect of two extensions in the MCR catchment area (from a base population of 2.51 million to 3.96 in 2002, and to 4.52 million in 2007). Death certificates from 2013 are incorporated into these analyses.
- Due to the high frequency and good prognosis of non-malignant skin cancer (C44), no systematic ascertainment is performed for this diagnosis. C44 is not designated as a primary, but rather as a secondary tumor.
- DCO (death certificate only) identifies a cancer case that first becomes available to the MCR through the death certificate. A high proportion of DCO cases (≥5%) in particular cancer types indicate insufficient participation of specific cancer specializations.

ICD-10 codes used for specifying cancer site

ICD-10	Description
C21 C21.0	Malignant neoplasm of anus and anal canal Anus, unspecified
C21.1	Anal canal
C21.2	Cloacogenic zone
C21.8	Overlapping lesion of rectum, anus and anal canal

INCIDENCE

Table 1

Patient cohorts by year of diagnosis including DCO cases and multiple primaries, and with proportion of deaths and active follow-up

				Prop.		Prop.
		DCO	Prop.	mult.	Prop.	actively
Year of	Cases	cases	DCO	primaries	deaths	followed
diagnosis	n	'n	%	96	%	%
1998	47			21.3	59.6	97.9
1999	36	/ 3	8.3	16.7	58.3	97.2
2000	48			27.1	60.4	100.0
2001	57	3	5.3	24.6	61.4	94.7
2002	70	2	2.9	31.4	62.9	97.1 #
2003	73	1	1.4	23.3	42.5	93.2 #
2004	82	3	3.7	24.4	39.0	97.6 #
2005	81	1	1.2	38.3	53.1	95.1 #
2006	82	4	4.9	31.7	46.3	96.3 #
2007	97	4	4.1	32.0	47.4	86.6 # ##
2008	91	1	1.1	19.8	41.8	74.7
2009	113	/ 1	0.9	29.2	34.5	68.1
2010	121	6	5.0	28.1	41.3	73.6
2011	100	1	1.0	18.0	24.0	80.0
2012	86			26.7	17.4	97.7 ###
1998-2012	1184	30	2.5	26.7	43.3	87.6

[#] The increases of incident cases in 2002 and 2007 reflect the expansion to additional registry areas.

^{##} Since 2007 the percentage of actively followed patients sharply declined compared to the previous years. This is a consequence of ambiguous data protection rules that currently forbid cancer registries in Bavaria to obtain the essential life status informations from competent registration offices.

^{###} Please be aware that data of recent annual patient cohorts may not yet be fully processed. Therefore, the presented figures and tables are potentially related to different time periods as pointed out in the respective headlines or legends.

Table 1a

Patient cohorts by year of diagnosis and gender including DCO cases

Year of	All	Males	Females	Prop. males	
diagnosis	n	n	n	%	
1998	47	14	33	29.8	
1999	36	/12	24	33.3	
2000	48	14	34	29.2	
2001	57	21	36	36.8	
2002	70	20	50	28.6	
2003	73	24	49	32.9	
2004	82	20	62	24.4	
2005	81	20	61	24.7	
2006	82	27	55	32.9	
2007	97	35	62	36.1	
2008	91	28	63	30.8	
2009	113	41	72	36.3	
2010	121	42	79	34.7	
2011	100	40	60	40.0	
2012	86	24	62	27.9	
1998-2012	1184	382	802	32.3	

Table 2

Incidence measures by year of diagnosis and gender including DCO cases (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

			Males	Fem.	Males	Fem.	Males	Fem.	Males	Fem.
Year of	Males	Females	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.	Inc.
diagnosis	n	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	14	33	1.3	2.8	0.8	1.4	1.1	2.0	1.4	2.5
1999	12	24	/1.1	2.0	0.7	1.0	0.9	1.4	1.2	1.6
2000	14	34	1.2	2.8	0.8	1.6	1.1	2.2	1.3	2.4
2001	21	36	1.8	3.0	1.0	1.5	1.5	2.1	1.8	2.5
2002	20	50	/ 1.1/	2.6	0.7	1.3	1.0	1.8	1.2	2.1
2003	24	49	1.3	2.5	0.8	1.4	1.2	1.9	1.3	2.1
2004	20	62	1.1	3.1	0.7	1.5	0.9	2.1	1.1	2.7
2005	20	61	1.1	3.1	0.7	1.4	0.9	2.0	1.1	2.6
2006	27	55	1.4	2.7	0.9	1.5	/ 1.1	2.1	1.3	2.4
2007	35	62	1.6	2.7	0.9	1.2	1.3	1.7	1.6	2.2
2008	28	63	1.3	2.7	0.7	1.3	1.0	1.8	1.2	2.2
2009	41	72	1.8	3.1	1.1	1.7	1.5	2.3	1.7	2.6
2010	42	79	1.9	3.4	0.9	1.6	1.4	2.3	1.8	2.8
2011	40	60	1.8	2.5	0.9	1.4	1.4	1.9	1.7	2.2
2012	24	62	1.1	2.6	0.5	1.3	0.8	1.9	1.0	2.2
1998-2012	382	802	1.4	2.8	0.8	1.4	1.2	2.0	1.4	2.3




Table 3

Age distribution parameters by year of diagnosis (All) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	47	64.5	14.6	34.3	90.7	48.1	52.1	64.0	78.2	84.5
1999	36	65.8	18.6	29.3	94.8	36.6	55.6	66.8	79.8	89.8
2000	48	63.2	12.2	34,7	89.8	50.8	55.0	62.0	71.0	82.4
2001	57	64.9	15,4	35.3	92.5	43.4	55.2	62.9	78.7	86.2
2002	70	65.8	12.6	41.6	89.2	49.1	56.8	63.2	75.9	83.2
2003	73	62.3	15.3	35.2	91.9	42.7	49.7	61.5	74.2	85.6
2004	82	66.2	14.4	28.1	95.9	47.7	54.7	66.0	79.7	83.1
2005	81	67.5	13.0	32.2	91.7	49.2	59.6	68.4	78.1	83.2
2006	82	63.7	13.4	28.5	93.2	45,3	54.2	63.6	71.8	83.2
2007	97	67.8	14.5	28.6	94.9	47.2	56.5	68.2	79.7	87.2
2008	91	66.2	13.8	33.6	93.9	47.0	57.1	67.9	75.7	85.3
2009	113	63.6	13.4	23.8	102	47.1	54.1	64.0	72.0	81.6
2010	121	67.4	13.5	36.9	94.4	50.1	57.5	67.8	77.5	84.9
2011	100	64.6	13.4	22.8	101	47.4	55.2	64.1	74.1	82.1
2012	86	67.2	15.0	37.2	96.5	49.2	54.7	67.8	80.7	86.8
1998-2012	1184	65.5	14.1	22.8	102	47.2	54.8	65.3	76.6	84.7

Table 3a

Age distribution parameters by year of diagnosis (MALES)

(incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	14	57.6	14.5	34.3	84.5	35.6	48.4	56.7	64.2	78.5
1999	12	60.2	19.4	29.3	86.7	30.8	45.8	64.7	72.5	84.2
2000	14	63.8	10.7	50.8	83.9	53.2	54.3	63.1	72.3	82.4
2001	21	61.6	13.2	37.4	82.1	42.8	56.4	61.8	66.8	79.3
2002	20	63.8	10.8	46.4	79.9	49.8	54.5	63.0	73.4	79.1
2003	24	59.5	13.2	35.2	85.9	41.3	50.4	58.2	68.9	76.3
2004	20	58.8	15.3	28.1	82.8	42.5	47.4	55.7	70.5	81.2
2005	20	62.5	10.1	47.8	82.6	50.7	54.7	60.6	69.7	77.7
2006	27	61.0	11.4	38.6	84.6	43.5	53.8	63.5	67.1	74.1
2007	35	66.6	13.4	45.4	93.9	47.5	56.1	66.1	79.0	87.2
2008	28	61.7	11.6	36.9	76.9	43.9	54.3	61.5	73.3	75.7
2009	41	63.3	13.3	37.5	102	46.3	54.1	65.5	70.0	77.8
2010	42	67.1	12.7	42.4	93.5	50.2	54.2	69.6	77.6	82.0
2011	40	64.5	12.8	33.3	89.4	48.5	54.4	64.3	75.4	79.3
2012	24	71.8	13.5	47.4	96.5	54.8	62.7	70.5	82.4	88.8
1998-2012	382	63.5	13.2	28.1	102	46.2	54.3	63.5	73.0	80.7

Table 3b

Age distribution parameters by year of diagnosis (FEMALES) (incl. DCO)

Year of	Cases		Std.					Median		
diagnosis	n	Mean	dev.	Min.	Max.	10%	25%	50%	75%	90%
1998	33	67.4	13.9	44.6	90.7	49.5	57.1	68.9	78.4	85.7
1999	24	68.6	17.9	34.3	94.8	40.1	56.6	71.5	83.7	90.2
2000	34	62.9	12.9	34.7	89.8	47.5	55.7	61.6	70.8	81.4
2001	36	66.9	16.3	35.3	92.5	45.0	53.6	67.8	82.7	87.9
2002	50	66.6	13.2	41.6	89.2	49.1	58.8	63.8	76.8	87.1
2003	49	63.7	16.2	36.1	91.9	42.7	49.4	63.1	76.7	88.0
2004	62	68.6	13.4	39.6	95.9	49.6	60.5	68.4	80.3	83.9
2005	61	69.2	13.4	32.2	91.7	46.4	62.4	70.9	79.4	84.6
2006	55	65.0	14.2	28.5	93.2	49.0	54.4	64.5	78.6	85.3
2007	62	68.6	15.2	28.6	94.9	44.6	57.7	70.0	80.2	87.0
2008	63	68.3	14.3	33.6	93.9	47.9	58.2	68.3	80.0	86.8
2009	72	63.7	13.6	23.8	88.9	47.3	54.1	63.0	72.7	82.9
2010	79	67.6	14.0	36.9	94.4	48.1	57.5	67.0	76.8	87.1
2011	60	64.6	13.9	22.8	101	47.4	55.7	63.4	72.6	82.8
2012	62	65.4	15.2	37.2	92.5	49.2	52.7	62.7	79.3	86.0
1998-2012	802	66.5	14.4	22.8	101	47.5	55.5	66.6	78.2	85.7

base_C21__E.pdf

Age at									
diagnosis	Cases			Males			Females		
Years	n	%	Cum.%	n	%	Cum.%	n	રુ	Cum.%
20-24	2	0.2	0.2			0.0	2	0.2	0.2
25-29	4	0.3	0.5	2	0.5	0.5	2	0.2	0.5
30-34	7	0.6	1.1	/ 3	0.8	1.3	4	0.5	1.0
35-39	22	1.9	3.0	9	2.4	3.7	13	1.6	2.6
40-44	53	4.5	7.4	19	5.0	8.6	34	4.2	6.9
45-49	89	7.5	14.9	25	6.5	15.2	64	8.0	14.8
50-54	123	10.4	25.3	47	12.3	27.5	76	9.5	24.3
55-59	123	10.4	35.7	50	13.1	40.6	73	9.1	33.4
60-64	161	13.6	49.3	51	13.4	53.9	110	13.7	47.1
65-69	145	12.2	61.6	54	14.1	68.1	91	11.3	58.5
70-74	123	10.4	72.0	39	10.2	78.3	84	10.5	69.0
75-79	118	10.0	81.9	42	11.0	89.3	76	9.5	78.4
80-84	102	8.6	90.5	26	6.8	96.1	76	9.5	87.9
85+	112	9.5	100.0	15	3.9	100.0	97	12.1	100.0
All ages	1184	100.0		382	100.0		802	100.0	

Included in the statistics are 30.1% multiple primaries in males and 36.3% in females.

Table 5

Age-specific incidence, DCO rate and proportion of all cancers for period 1998-2012

Age at diagnosis Years	Males n	Females n	Age- spec. incid.	Age-spec.incid.	Males DCO rate n=8	Females DCO rate n=22 %		Females Prop.all cancers n=142297
5- 9			0.0	0.0				
10-14			0.0	0.0				
15-19		0	0.0	0.0				0 4
20-24 25-29	2	2 2	0.0	0.1 0.1			0.2	0.4 0.2
30-34	3	4	0.1	0.1			0.2	0.2
35-39	9	13	0.1	0.6			0.4	0.2
40-44	19	34	0.4	1.5			0.4	0.4
45-49	25	64	1.2	3.0			0.5	0.8
50-54	47	76	2.5	4.0			0.6	0.7
55-59	50	73	2.9	4.1	2.0		0.4	0.6
60-64	51	110	3.1	6.3	2.0		0.2	0.7
65-69	54	91	3.7		3.7		0.2	0.5
70-74	39	84	3.4	6.1	2.6		0.2	0.5
75-79	42	76	5.6	6.9	4.8	3.9	0.2	0.5
80-84	26	76	5.7	8.8	3.8	9.2	0.2	0.5
85+	15	97	4.8	11.8	6.7	12.4	0.2	0.6
		\			0 1		\	0 6
All ages	382	802			2.1	2.7	0.3	0.6
	382	802			2.1	2.7	0.3	0.6
Incidence	382	802	1 4	2 Q	2.1	2.7	0.3	0.6
Incidence Raw	382	802	1.4	2.8		2.7	0.3	0.6
Incidence Raw WS	382	802	0.8	1.4		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS	382	802	0.8	1.4		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6
Incidence Raw WS ES	382	802	0.8	1.4 2.0		2.7	0.3	0.6

The age-specific incidence characterizes the disease risk in a particular age group. The age distribution depends on the patient population frequency in each age group and reflects the tangible clinical picture of everyday patients care (see following chart).

DCO

Table 6a

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of second primaries for period 1998-2012

MALES

LCL

UCL

Observed Expected

Diagnosis	n	n	SIR	95%		EAR	
C03-C06 Oral cavity C09-C10 Oropharynx C16 Stomach C18 Colon C19-C20 Rectum	2 2 3 2 4	0.1 0.2 0.6 1.4 0.8	14.6 11.6 5.1 1.5 5.0	1.8 1.4 1.0 0.2 1.4		18.4 24.3 6.3	
C33-C34 Lung C61 Prostate	5 6	1.6	3.1 1.5	1.0	7.1	33.9 19.1	
Other primaries Not observed	6	2.0	3.0	1.1	6.5 # 1.1	40.2 -34.1	
All mult. primaries	30	14.2	2.1	1.4	3.0 #	159.2	
Patients Mean age at second mali Person-years Mean observation time		ars) 66	275 5.5 993 3.6				

The occurrence of second malignancy is statistically significant.

Median observation time (years)

Observed second primaries with count 1 are pooled in category "Other primaries".

2.5

Table 6b

Standardized incidence ratio (SIR, with 95% confidence limits), excess absolute risk (EAR) and DCO rate of second primaries for period 1998-2012

FEMALES

		Observed	Expected		LCL	UCL		DCO
Diagnos	is	n /	n	SIR	95%	95%	EAR	%
C16	Stomach	2/	1.0	2.0	0.2	7.1	4.0	
C17	Small intestine	2	0.1	16.1	2.0	58.3 #	7.6	
C18	Colon	12	2.8	4.3	2.2	7.6 #	37.4	33.3
C19-C20	Rectum	/ 4 /	1.2	3.3	0.9	8.5	11.3	
C25	Pancreas	/ 3 /	1.2	2.5	0.5	7.4	7.4	
C33-C34	Lung	/ 14 /	1.9	7.4	4.0	12.4 #	49.1	7.1
C50	Breast	/ 15	8.4	1.8	1.0	3.0 #	26.9	6.7
C51	Vulva	3	0.3	11.4	2.3	33.3 #	11.1	
C53	Cervix uteri	3	0.4	7.8	1.6	22.8 #	10.6	33.3
C54	Corpus uteri	2	1.5	1.3	0.2	4.8	2.1	
C56	Ovary	2	1.1	1.8	0.2	6.4	3.5	
C73	Thyroid	3	0.5	6.0	1.2	17.4 #	10.1	
C82-C85	NHL	3	1.0	2.9	0.6	8.5	8.0	
C91-C96	Leukaemia	3	0.4	7.0	1.4	20.5 #	10.4	33.3
Other p	rimaries	8	3.2	2.5	_1.1	4.9 #	19.5	12.5
Not obse	erved	0	2.5	0.0	0.0	1.5	-10.2	
All mul	t. primaries	79	27.5	2.9	2.3	3.6 #	209.0	11.4

Patients	606
Mean age at second malignancy (years)	72.0
Person-years	2465
Mean observation time (years)	4.1
Median observation time (years)	3.2

The occurrence of second malignancy is statistically significant.

Observed second malignancies with count 1 are pooled in category "Other primaries".




Figure 7. Age distribution and age-specific incidence



C21: Malignant neoplasm of anus and anal canal Age-specific incidence in international comparison




Figure 7a. Age-specific incidence in MCR registry areas compared to SEER (Surveillance, Epidemiology, and End Results, USA).




Reference:

Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 18 Regs Research Data, released April 2012, based on the November 2011 submission. http://www.seer.cancer.gov.


C21: Malignant neoplasm of anus and anal canal Cumulative follow-up years since diagnosis for period 1998 - 2012 (excl. DCO) Target 550 Gender Sum Median Sum Median All patients 500 Males 262 1122 1032 2.9 Females 571 2707 3.8 2541 3.6 450 Patients alive 146 836 4.4 Males 4.9 746 400 372 2205 5.3 2040 4.8 Cumulative follow-up years 350 300 250 200 150 100 50 in 13. 12 Follow-up year since diagnosis

Figure 8. Cumulative follow-up years depending on time since diagnosis

The increase of the lost to follow-up rate can be interpreted as a consequence of a declining number of survivors over time.



Average incidence (world standard population) 2003 - 2008: Males



Average incidence (world standard population) 2003 - 2008: Females



Figure 9a. Map of cancer incidence (world standard population, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual incidence rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.8/100,000 WS N=148, females 1.4/100,000 WS N=346). Since cancer data are not available in some counties until 2007, the local incidence rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 8 women were identified with newly diagnosed anal cancer. Therefore, the mean incidence rate for this cancer type in this area can be calculated at 1.3/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.4 and 3.2/100,000.

Standardized incidence ratio (SIR) 2003 - 2008: Males






Figure 9b. Map of standardized incidence ratio (SIR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SIR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=148, females N=346). Since cancer data are not available in some counties until 2007, the local SIR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 8 women were identified with newly diagnosed anal cancer. Therefore, the mean standardized incidence ratio (SIR) for this cancer type in this area can be calculated at 0.78. Though, the value of this parameter may vary with an underlying probability of 99% between 0.25 and 1.80, and is therefore not statistically striking.

MORTALITY

Table 10a

Patient cohorts of incident cancers by year of diagnosis, follow-up status, proportion of DCO, deaths among the annual cohorts, and proportion of available death certificates (with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

		Prop.				Prop. deaths
	Incident	actively	Prop.		Prop.	with death
Year of	cases	followed	DCO	Deaths	deaths	certific.
diagnosis	n	%	%	/ n /	%	%
1998	47	97.9		28	59.6	89.3
1999	36	97.2	8.3	21	58.3	90.5
2000	48	100.0		29	60.4	93.1
2001	57	94.7	5.3	35	61.4	97.1
2002	70	97.1	2.9	44	62.9	97.7
2003	73	93.2	1.4	31	42.5	100.0
2004	82	97.6	3.7	32	39.0	100.0
2005	81	95.1	1.2	43	53.1	97.7
2006	82	96.3	4.9	38	46.3	100.0
2007	97	86.6	4.1	46	47.4	97.8
2008	91	74.7	1.1	38	41.8	100.0
2009	113	68.1	0.9	39	34.5	100.0
2010	121	73.6	5.0	50	41.3	98.0
2011	100	80.0	1.0	24	24.0	95.8
2012	86	97.7		15	17.4	86.7
1998-2012	1184	87.6	2.5	513	43.3	97.1

Table 10b

Annual cohorts of incident cancers and deaths, proportion of death certificates and cases deceased the same year of cancer diagnosis (incl. DCO)

			Prop.		
			deaths		Prop.
Year of	Incident		with death	Deaths in	deaths in
diagnosis/	cases	Deaths	certific.	same year	same year
death	n	n	%	n	%
1998	47	14	85.7	4	8.5
1999	36	13	84.6	1	2.8
2000	48	19	84.2	4	8.3
2001	57	30	96.7	8	14.0
2002	70	38	97.4	8	11.4
2003	73	31	100.0	5	6.8
2004	82	36	100.0	5	6.1
2005	81	52	96.2	11	13.6
2006	82	47	100.0	7	8.5
2007	97	49	93.9	8	8.2
2008	91	48	97.9	6	6.6
2009	/113	42	100.0	_ 4	3.5
2010	121 /	73	100.0	20	16.5
2011	100	72	97.2	11	11.0
2012	86	59	100.0	10	11.6
1998-2012	1184	623	97.3	112	9.5

Table 10c

Annual cohorts of deaths, proportion of cancer-related and not cancer-related deaths, and cancer recorded on death certificates (incl. DCO)

(with respect to registry area expansion from 2.51 to 3.96 m as of 2002, and from 3.96 to 4.52 m as of 2007, respectively)

				Prop. cancer	
		Prop.	Prop.	recorded	
		/ -			
	, /	cancer-	not cancer-	on death	
Year of	Deaths	related	related	certificate	
death	n	%	8	%	
1998	14	64.3	35.7	91.7	
1999	13	46.2	53.8	81.8	
2000	19	89.5	10.5	100.0	
2001	30	63.3	36.7	86.2	
2002	38	86.8	13.2	91.9	
2003	31	83.9	16.1	90.3	
2004	36	75.0	25.0	86.1	
2005	52	80.8	19.2	88.0	
2006	47	66.0	34.0	80.9	
2007	49	63.3	36.7	78.3	
2008	48	75.0	25.0	87.2	
2009	42	69.0	31.0	92.9	
2010	73	74.0	26.0	86.3	
2011	72	76.4	23.6	87.1	
2012	59	66.1	33.9	74.6	
1998-2012	623	72.9	27.1	85.8	

Table 11a $\begin{tabular}{ll} Means of age at death according to the grouping in Table 10 \\ \hline MALES \end{tabular}$

					Age at
		Age at	Age at	Age at	death
		death	death	death	(according
		(all	(cancer-	(not cancer-	to death
Year of	Deaths	causes)	related)	related)	certificate)
death	n	Years	Years	Years	Years
1998	3	56.7	46.7	61.7	56.7
1999	3	60.2	62.8	58.9	62.8
2000	4	63.6	55.3	88.4	69.5
2001	13	72.4	71.6	75.2	73.1
2002	11	59.4	54.7	67.8	57.8
2003	12	60.9	57.8	76.5	59.6
2004	12	69.3	67.9	72.1	67.5
2005	17	66.1	65.1	68.5	65.1
2006	16	65.9	62.6	70.3	65.6
2007	15	73.1	73.2	73.0	75.0
2008	17	66.8	66.1	69.4	67.5
2009	10	70.1	63.8	79.6	68.8
2010	32	68.5	70.3	60.8	70.2
2011	26	71.6	71.1	73.4	70.6
2012	21	70.6	68.6	75.7	71.7
1998-2012	212	68.0	66.7	70.9	68.1

Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 11b Means of age at death according to the grouping in Table 10 FEMALES

Year of	Deaths	Age at death (all causes)	Age at death (cancer-related)	Age at death (not cancer- related)	Age at death (according to death certificate)
death	n	Years	Years	Years	Years
1998	11	73.9	70.7	82.4	73.7
1999	10	79.3	72.5	86.2	77.3
2000	15	74.1	76.9	34.8	76.6
2001	17	79.6	75.4	84.3	80.8
2002	27	77.1	77.8	60.4	77.0
2003	19	78.5	77.2	85.3	78.0
2004	24	79.6	76.4	91.6	78.6
2005	35	76.8	75.3	85.2	75.9
2006	31	75.7	76.2	74.4	77.3
2007	34	76.6	73.3	83.5	73.8
2008	31	79.3	77.6	84.4	78.8
2009	32	75.0	73.6	78.6	74.5
2010	41/	77.2	73.4	85.3	76.0
2011	46	75.7	74.2	80.7	75.9
2012	38	78.0	75.4	82.6	75.6
1998-2012	411	77.0	75.3	82.2	76.5



Deaths of patients are considered to be cancer-related, in case that fact was recorded on the death certificate, or patients had suffered from metastasis or recurrence.

Table 12a $\begin{tabular}{ll} Mortality measures (cancer-related death) and mortality-incidence-index \\ by year of death \\ \hline MALES \\ \end{tabular}$

Year of death	Deaths			Mort. WS	MI-Index WS	Mort. ES	MI-Index ES	Mort. BRD-S	MI-Index BRD-S
ueatii	n	raw	raw	WS	WB	FD	EО	מ-מאם	PKD-2
1998	1	0.1	0.07	0.1	0.10	0.1	0.08	0.1	0.08
1999	1	0.1	0.08	0.1	0.08	0.1	0.07	0.1	0.06
2000	3	0.3	0.21	0.2	0.27	0.3	0.24	0.3	0.21
2001	10	0.9	0.48	0.5	0.46	0.8	0.53	1.0	0.58
2002	7	0.4	0.35	0.3	0.41	0.4	0.37	0.4	0.32
2003	10	0.5	0.42	0.3	0.42	0.5	0.39	0.5	0.40
2004	8	0.4	0.40	0.2	0.32	0.3	0.35	0.5	0.42
2005	12	0.6	0.60	0.3	0.48	0.5	0.50	0.6	0.58
2006	9	0.5	0.33	0.3	0.34	0.4	0.38	0.5	0.39
2007	8	0.4	0.23	0.2	0.22	0.3	0.22	0.3	0.21
2008	13	0.6	0.46	0.3	0.42	0.5	0.44	0.6	0.48
2009	6	0.3	0.15	0.1	0.14	0.2	0.14	0.2	0.14
2010	26	1.2	0.62	0.6	0.60	0.8	0.61	1.1	0.61
2011	20	0.9	0.50	0.4	0.45	0.7	0.48	0.9	0.52
2012	15	0.7	0.63	0.3	0.63	0.5	0.63	0.6	0.63
1998-2012	149	0.5	0.39	0.3	0.36	0.4	0.38	0.5	0.40

Table 12b

Mortality measures (cancer-related death) and mortality-incidence-index by year of death

FEMALES

Year of	Deaths	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index	Mort.	MI-Index
death	n	raw	raw	WS	WS	ES	ES	BRD-S	BRD-S
1998	8	0.7	0.24	0.3	0.20	0.4	0.22	0.5	0.21
1999	5	0.4	0.21	0.2	0.19	0.3	0.21	0.3	0.22
2000	14	1.2	0.41	0.4	0.27	0.7	0.30	0.9	0.38
2001	9	0.7	0.25	0.3	0.20	0.5	0.22	0.6	0.25
2002	26	1.3	0.52	0.4	0.33	0.7	0.38	1.0	0.45
2003	16	0.8	0.33	0.3	0.21	0.4	0.24	0.6	0.28
2004	19	1.0	0.31	0.4	0.24	0.6	0.27	0.7	0.27
2005	30	1.5	0.49	0.5	0.37	0.8	0.40	1.1	0.45
2006	22	1.1	0.40	0.4	0.27	0.6	0.29	0.8	0.33
2007	23	1.0	0.37	0.4	0.32	0.6	0.34	0.8	0.35
2008	23	1.0	0.37	0.3	0.25	0.5	0.28	0.7	0.33
2009	23	1.0	0.32	0.4	0.23	0.6	0.25	0.7	0.27
2010	28	1.2	0.35	0.5	0.28	0.7	0.29	0.8	0.30
2011	35	1.5	0.58	0.6	0.41	0.9	0.45	1.1	0.50
2012	24	1.0	0.39	0.4	0.27	0.6	0.29	0.7	0.33
1998-2012	305	1.1	0.38	0.4	0.28	0.6	0.30	0.8	0.34

Table 13

Age distribution of age at death (cancer-related) for period 1998-2012 (incl. multiple primaries)

Age at				_			_		
death	Cases			Males			Females		
Years	n	% C	um.%	n	%	Cum.%	n	%	Cum.%
30-34	1	0.2	0.2			0.0	1	0.3	0.3
35-39	2	0.4	0.7	2	1.3	1.3			0.3
40-44	11	2.4	3.1	8	5.4	6.7	3	1.0	1.3
45-49	25	5.5	8.6	8	5.4	12.1	17	5.6	6.9
50-54	24	5.3	13.9	10	6.7	18.8	14	4.6	11.5
55-59	32	7.0	20.9/	18	12.1	30.9	14	4.6	16.1
60-64	40	8.8	29.7	16	10.7	41.6	24	7.9	23.9
65-69	48	10.6	40.3	23	15.4	57.0	25	8.2	32.1
70-74	56	12.3	52.6	21	14.1	71.1	35	11.5	43.6
75-79	49	10.8	63.4	20	13.4	84.6	29	9.5	53.1
80-84	66	14.5	78.0	13	8.7	93.3	53	17.4	70.5
85+	100	22.0 1	00.0	10	6.7	100.0	90	29.5	100.0
All ages	454	100.0		149	100.0		305	100.0	

Included in the statistics are 30.1% multiple primaries in males and 36.3% in females.

Table 14

Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2012 (incl. multiple primaries)

			Males		Females		Males	Females
Age at			Age-		Age-		Prop.all	Prop.all
death	Males	Females	spec.		spec.		cancers	cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	%	%
0 - 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34		1 <	0.0		0.0	0.25		0.5
35-39	2		0.1		0.0		0.5	
40-44	8	3	0.3	0.42	0.1	0.09	1.0	0.3
45-49	8	17	0.4		0.8	0.27	0.5	0.9
50-54	10	14	0.5	0.21	0.7	0.18	0.3	0.5
55-59	18	14	1.1	0.36	0.8		0.3	0.3
60-64	16	24	1.0	0.31	1.4	0.22	0.2	0.4
65-69	23	25	1.6		1.6		0.2	0.3
70-74	21	35	1.8		2.5	0.42	0.2	0.4
75-79	20	29	2.7		2.7		0.2	0.3
80-84	13	53	2.9		6.1	0.70	0.1	0.5
85+	10	90	3.2	0.67	11.0	0.93	0.1	0.7
All ages	149	305					0.2	0.5
Mortality								
Raw			0.5		1.1	0.38		
WS			0.3		0.4	0.28		
ES			0.4		0.6	0.30		
BRD-S			0.5	0.40	0.8	0.34		
PYLL-70								
per 100,000			4.2		4.7			
ES			3.6		4.1			
AYLL-70			12.3		11.9			

The rates underestimate the prognosis if other synchronous cancers are prognostic unfavorable.

Table 15a $\begin{tabular}{ll} Multiple primaries in deaths in period 1998-2012 \\ \hline MALES \end{tabular}$

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n /	%↓	n	←%	n	←%	n	~ %
C03-C06 Oral cavity	1	1.6	1	100.0				
C09-C10 Oropharynx	4	6.6	1	25.0	\ 1	25.0	2	50.0
C12-C13 Hypopharynx	2	3.3	1	50.0			1	50.0
C15 Oesophagus	2	3.3	1	50.0			1	50.0
C16 Stomach	2	3.3	1	50.0			1	50.0
C18 Colon	/ 7 /	11.5	4	57.1			3	42.9
C19-C20 Rectum	6	9.8			2	33.3	4	66.7
C22 Liver	1	1.6	1	100.0				
C32 Larynx	1	1.6	1	100.0				
C33-C34 Lung	8	13.1			3	37.5	5	62.5
C43 Malign. melanoma	2	3.3	1	50.0			1	50.0
C44 Skin others	5	8.2	2	40.0			3	60.0
C61 Prostate	8	13.1	3	37.5	1	12.5	4	50.0
C64 Kidney	1	1.6	1	100.0				
C67 Bladder	4	6.6	2	50.0	1	25.0	1	25.0
C70-C72 CNS cancer	3	4.9	1	33.3	_ 1	33.3	/1	33.3
C82-C85 NHL	3	4.9	2	66.7			1	33.3
C91-C96 Leukaemia	1	1.6					1	100.0
All mult. primaries	61	100.0	23	37.7	9	14.8	29	47.5




Table 15b

Multiple primaries in deaths in period 1998-2012
FEMALES

					Syn- chron	Syn- chron		
	Total	Total	Pre	Pre	±30d	±30d	Post	Post
Diagnosis	n /	%↓	n	-%	n	-30d -%	n	-%
2 10.3110.2 12	/	• •						
C03-C06 Oral cavity	3	1.9	3	100.0				
C09-C10 Oropharynx	/3	1.9	1	33.3			2	66.7
C15 Oesophagus	/ 2	1.3			1	50.0	1	50.0
C16 Stomach	/ 7	4.4	1	14.3			6	85.7
C17 Small intestine	/ 1	0.6					1	100.0
C18 Colon	20 /	12.6	6	30.0	3	15.0	11	55.0
C19-C20 Rectum	6	3.8	1	16.7	4	66.7	1	16.7
C21 Anus/canal	2	1.3			/ 1	50.0	1	50.0
C25 Pancreas	4	2.5					4	100.0
C33-C34 Lung	16	10.1	2	12.5	2	12.5	12	75.0
C43 Malign. melanoma	1	0.6	1	100.0				
C44 Skin others	5	3.1	1	20.0			4	80.0
C48 Peritoneal	1	0.6					1	100.0
C50 Breast	23	14.5	12	52.2	4	17.4	7	30.4
C51 Vulva	7	4.4	3	42.9			4	57.1
C52 Vagina	2	1.3	2	100.0				
C53 Cervix uteri	17	10.7	15	88.2			2	11.8
C54 Corpus uteri	6	3.8	3	50.0			3	50.0
C56 Ovary	2	1.3	2	100.0				
C64 Kidney	2	1.3	1	50.0	1	50.0		
C67 Bladder	2	1.3	2	100.0				
C70-C72 CNS cancer	4	2.5	1	25.0	1	25.0	2	50.0
C73 Thyroid	3	1.9					3	100.0
C76-C79 CUP	2	1.3					2	100.0
C81 Hodgkin lymphoma	1	0.6	1	100.0				
C82-C85 NHL	10	6.3	6	60.0			4	40.0
C90 Mult. myeloma	2	1.3					2	100.0
C91-C96 Leukaemia	5	3.1	1	20.0			4	80.0
All mult. primaries	159	100.0	65	40.9	17	10.7	77	48.4

Multiple primaries with number of cases n<1 are pooled in category "Other primaries".

ICD-10 C44 (Other malignant neoplasms of skin) is not systematically recorded by MCR and therefore not considered for evaluation as a particular primary but at least as a multiple malignancy.

base_C21__E.pdf

Table 16

Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2012

(Singular primaries only *)

Age at		_	Males Age-		Females Age-		_	Females Prop.all
death		Females	spec.		spec.		cancers	cancers
Years	n	n	mortal.	MI-index	mortal.	MI-index	%	%
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34		1 <	0.0		0.0	0.33		0.5
35-39	1	_	0.0	0.13	0.0	,	0.3	
40-44	8	1	0.3		0.0	0.03	1.1	0.1
45-49	6	17	0.3	0.29	0.8	0.29	0.4	1.0
50-54	9	11	0.5	0.21	0.6	0.16	0.3	0.5
55-59	15	13	0.9	0.33	0.7	0.21	0.3	0.3
60-64	14	19	0.8	0.32	1.1	0.22	0.2	0.4
65-69	17	17	1.2	0.38	1.1	0.24	0.2	0.3
70-74	16	25	1.4		1.8	0.40	0.2	0.3
75-79	14	20	1.9		1.8		0.2	0.3
80-84	12	40	2.6	0.60	4.6		0.2	0.5
85+	8	70	2.6	0.62	8.5	0.91	0.1	0.7
	\	\						
All ages	120	234					0.2	0.4
3.1								
Mortality			0.4	0 27	0 0	0.36		
Raw			0.4	0.37 0.34	0.8			
WS ES			0.2		0.3	0.26		
BRD-S			0.4	0.38	0.5	0.29		
PKD-2			0.4	0.30	0.0	0.32		
PYLL-70								
per 100,000			3.6		4.0			
ES			3.1		3.5			
AYLL-70			12.6		12.5			

^{*} See corresponding tables with multiple primaries.

Table 17

Age-specific mortality (cancer-related) and proportion of all cancers for period 1998-2012

(Single primaries only *)

Age at death	Males	Females	Males Age- spec.		Females Age- spec.		Males Prop.all cancers	Females Prop.all cancers
Years	n	n		MI-index		MI-index	%	%
0- 4			0.0		0.0			
5- 9			0.0		0.0			
10-14			0.0		0.0			
15-19			0.0		0.0			
20-24			0.0		0.0			
25-29			0.0		0.0			
30-34		1 <	0.0		0.0	0.33		0.6
35-39			0.0		0.0			
40-44	7		0.3		0.0		1.0	
45-49	4	17	0.2	0.24	0.8	0.32	0.3	1.2
50-54	8	10	0.4	0.20	0.5	0.16	0.3	0.5
55-59	13	10	0.8	0.33	0.6	0.19	0.3	0.3
60-64	8	13	0.5	0.21	0.7	0.17	0.1	0.3
65-69	13	12	0.9	0.32	0.7	0.18	0.2	0.2
70-74	13	19	1.1		1.4	0.34	0.2	0.3
75-79	12	1/7	1.6		1.6	0.39	0.2	0.3
80-84	11	28	2.4		3.2	0.54	0.2	0.4
85+	8	57	2.6	0.62	7.0	0.79	0.2	0.6
All ages	97	184					0.2	0.4
Mortality								
Raw			0.4		0.6	0.32		
WS			0.2		0.2	0.23		
ES			0.3		0.4	0.26		
BRD-S			0.4	0.35	0.5	0.28		
PYLL-70								
per 100,000			2.7		3.5			
ES			2.4		3.0			
AYLL-70			12.8		13.5			

^{*} See corresponding tables with multiple primaries.

C21: Malignant neoplasm of anus and anal canal





Figure 18. Distribution of age at death (bars) and age-specific mortality (all patients: solid line, patients with single primaries: dotted line). The age-specific incidence is additionally plotted for comparison (dashed line).

The difference between age at diagnosis (Table 3) and age at anal cancer-related death (see Table 10) should be considered.



Average mortality (world standard population) 2003 - 2008: Males



Average mortality (world standard population) 2003 - 2008: Females





Figure 19a. Map of cancer mortality (world standard population) by county averaged for period 2003 to 2008. According to their individual mortality rates, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population mean (males 0.3/100,000 WS N=58, females 0.4/100,000 WS N=132). Since cancer data are not available in some counties until 2007, the local mortality rates were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 3 women died from anal cancer. Therefore, the mean mortality rate for this cancer type in this area can be calculated at 0.4/100,000 (world standard population). Though, the value of this parameter may vary with an underlying probability of 99% between 0.0 and 1.7/100,000.

Standardized mortality ratio (SMR) 2003 - 2008: Males



Standardized mortality ratio (SMR) 2003 - 2008: Females



Figure 19b. Map of standardized mortality ratio (SMR, incl. DCO cases) by county averaged for period 2003 to 2008. According to their individual SMR values, the counties are displayed in different red and blue color temperatures where the fine white color indicates the population overall of 1.0 (males N=58, females N=132). Since cancer data are not available in some counties until 2007, the local SMR values were not calculated, and the map tiles show as shaded.

The results should be interpreted with caution! E.g., in county Ebersberg with a population of 63,131 female residents (averaged) in the period from 2003 to 2008 a total of 3 women died from anal cancer. Therefore, the mean standardized mortality ratio (SMR) for this cancer type in this area can be calculated at 0.81. Though, the value of this parameter may vary with an underlying probability of 99% between 0.09 and 2.97, and is therefore not statistically striking.

Statistical Notes

In all tables and figures the respective reference values should be carefully considered. The incidence rates include diagnoses (with multiple primary), and death certificate only (DCO) cases. For mortality statistics patients, diagnoses and progressive course of disease are presented. In the calculations, all courses of disease are considered whereby progressions occurred and/or death certificate identified progressive cancers were ascertained. Additionally there are three groups of disease course to consider:

1. All multiple primaries included

The mortality statistic describes the tumor-specific death, independent of any malignancy. The patient perspective, induced secondary malignancies, and the problem of multiple malignancies from the same primary tumor all have reasons for their inclusion.

2. First singular primary (no information about other prior or synchronous malignancy)

The mortality statistic describes the tumor-related death for patients who have no therapeutic restrictions due to a previous or synchronous cancer. These statistics are comparable to studies that have exclusion criteria based on a second malignancy.

3. Single primary (no information about other prior, syn- or metachronous malignancy)

The mortality statistic describes the tumor-specific death that occurs without any impact through secondary primaries, earlier, synchronous, later or induced. Precisely the difference between disease group 1 and 2 highlight the magnitude of the problem of secondary malignancies.

For this reason differences appear concerning official mono-causal mortality statistics. To judge the maximum deviation, 2 further tables are presented. In the first table the distribution of secondary malignancies before, at or after the described cancer are shown, that could be an alternative cause of death. In the second table, the age-specific mortality rates for all courses of disease, without designation of secondary malignancies are shown.

A previously minimally acknowledged statistic is the **age at death**, which allows for a good assessment of the quality of classification of the apparent tumor-specific death. For assumed tumor-independent deaths, the age of death should be estimated from the age of diagnosis and the normal life expectancy, whereas tumor-dependent deaths can be estimated from the age of diagnosis plus the average tumor-specific life expectancy. The comparison of different tumors demonstrates this association, if the causes of cancer and the competing cause of death are independent of each other (e.g. breast and colon versus head/neck and lung).

The index from mortality and incidence (Mortality-Incidence ratio, **MI-index**) is a statistic that allows for the evaluation of the quality of data. For diseases with poor prognoses, comparable values are obtained from all age groups, because to a large extent, the numerator and denominator contain the same cases. For tumors with a good prognosis, increasing and decreasing incidence and age-specific differences in prognosis can more strongly alter the MI- index. Additionally, attention should be paid to the confidence intervals where fewer cases are reported.

The complexity of problems identified here emphasizes the importance of relative survival data for the appropriate analysis of long term results.

As a measurement of the burden of disease, the number of potential life years loss due to premature deaths in a cohort can be calculated (**PYLL**, potential years of life lost, standardized per 100,000 persons or per European standard) as well as the average loss of life years per individual (**AYLL**, average years of life lost). Depending upon the analytic aim (health economy, prevention, health care research) different methods exist for the generation of these measurements. In the results presented here, the age for a premature death is considered to be before 70 years, according to the guidelines of the OECD and the WHO (as seen in the abbreviation PYLL-70 or AYLL-70).

Shortcuts

AYLL-70 Average years of life lost prior to age 70 given a person dies before that age

BRD-S German standard population

DCO Death certificate only EAR Excess absolute risk

= excess cancer cases (O - E) per 10,000 person-years

ES European standard population (old) FRG Federal Republic of Germany

GEKID Association of Population-based Cancer Registries in Germany

(Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V.)

LCL Lower confidence limit

MI-index Ratio between mortality and incidence

MCR Munich Cancer Registry (Tumorregister München)

PYLL-70 Potential years of life lost prior to age 70 given a person dies before that age

SEER Surveillance, Epidemiology, and End Results (USA)

SIR Standardized incidence ratio
SMR Standardized mortality ratio
UCL Upper confidence limit
WS World standard population

Recommended Citation

Munich Cancer Registry. Baseline statistics C21: Anal cancer [Internet]. 2014 [updated 2014 Mar 20; cited 2014 May 1]. Available from: http://www.tumorregister-muenchen.de/en/facts/base/base_C21__E.pdf

Copyright

The content of the public web site provided by the Munich Cancer Registry is available worldwide and free of charge. All documents are free to download, utilize, copy, print-out and distribute, providing that the MCR is referenced.

Disclaimer

The Munich Cancer Registry reserves the right to not be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Index of figures and tables

Fig./Tbl	l.	Page
1	Pts cohorts, DCO, mult. prim., follow-up / yr	3
1a	Gender distribution by year of diagnosis	4
2	Incidence by year of diagnosis	5
3	Age distribution parameters by year of diagnosis	6
4	Age distribution by 5-year age group and gender	8
5	Age-specific incidence and DCO rate	9
6	Standardized incidence ratio of second primaries	10
7	Age distribution and age-specific incidence (chart)	12
7a	Age-specific incidence internationally (chart)	13
8	Cumulative follow-up years (chart)	14
9a	Map of cancer incidence (WS) by county (chart)	15
9b	Standardized incidence ratio (SIR) by county (chart)	16
10a	Pts incident cohorts and mortality / yr	17
10b	Incidence and mortality by year of diagnosis	18
10c	Cancer-related deaths, death certification available / yr	19
11	Means of age at death / yr	20
12	Mortality by year of death	22
13	Distribution of age at death	23
14	Age-specific mortality	24
15	Multiple primaries in deaths	25
16	Age-specific mortality (first primaries)	27
17	Age-specific mortality (single primaries)	28
18	Age distribution and age-specific mortality (chart)	29
19a	Map of cancer mortality (WS) by county (chart)	30
19b	Standardized mortality ratio (SMR) by county (chart)	31